Gamble of the week: promising biotech firm

This week's gamble is a science-rich company with solid long-term prospects in a niche sector, whose present downtrodden valuation does not reflect its potential.

This company supplies human tissue and other biomaterials, such as blood and DNA, to the pharmaceutical and biotechnology industries. The group collects these products from hospitals and medical premises around the world, stores them in specially controlled conditions and then sells them to healthcare firms for use in their research. These substances typically fill the gap between preclinical (animal) and Phase I (human) trials, with the aim of shortening drug development times and weeding out ineffectual treatments earlier in process.

Asterand (LSE:ATD)

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

Paul gained a degree in electrical engineering and went on to qualify as a chartered management accountant. He has extensive corporate finance and investment experience and is a member of the Securities Institute.

Over the past 16 years Paul has held top-level financial management and M&A roles for blue-chip companies such as O2, GKN and Unilever. He is now director of his own capital investment and consultancy firm, PMH Capital Limited.

Paul is an expert at analysing companies in new, fast-growing markets, and is an extremely shrewd stock-picker.